Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

被引：1
作者：
Ouissam, Al Jarroudi [1 ,2 ]
Hind, Chibani [1 ,2 ]
Aziz, Brahmi Sami [1 ,2 ]
Said, Afqir [1 ,2 ]
机构：
[1] Mohammed VI Univ Hosp, Dept Med Oncol, Oujda, Morocco
[2] Mohammed Ist Univ, Fac Med & Pharm, Oujda, Morocco
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷
关键词：
clinical trials; genetic alterations; pancreatic ductal adenocarcinoma; PI3K/AKT/mTOR pathway; targeted therapy; GROWTH-FACTOR RECEPTOR; 1ST-IN-HUMAN PHASE-I; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PI3K INHIBITOR; PHOSPHOINOSITIDE; 3-KINASE; PI3K/MTOR INHIBITOR; ANTITUMOR-ACTIVITY; BUPARLISIB BKM120;
D O I：
10.1177/17588359241284911
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.
引用
收藏
页数：21
相关论文
共 50 条
  • [31] Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
    Dong, Chao
    Wu, Jiao
    Chen, Yin
    Nie, Jianyun
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [32] Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
    Aggarwal, Sadhna
    John, Sarah
    Sapra, Leena
    Sharma, Suresh C.
    Das, Satya N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 451 - 461
  • [33] Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer
    Alves, Carla L.
    Ditzel, Henrik J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [34] The PI3K/AKT Pathway as a Target for Cancer Treatment
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 11 - 28
  • [35] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [36] Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
    Yu, Le
    Wei, Jessica
    Liu, Pengda
    SEMINARS IN CANCER BIOLOGY, 2022, 85 : 69 - 94
  • [37] Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
    Zhao, Zhong-Quan
    Yu, Zhong-Yang
    Li, Jie
    Ouyang, Xue-Nong
    ONCOLOGY LETTERS, 2016, 12 (01) : 63 - 68
  • [38] Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
    Gonzalez-Angulo, A. M.
    Blumenschein, G. R., Jr.
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 313 - 320
  • [39] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [40] Ilicicolin C suppresses the progression of prostate cancer by inhibiting PI3K/AKT/mTOR pathway
    Gan, Xia
    Luo, Xiaowei
    Chen, Jingqin
    Fang, Wenxuan
    Nie, Mingyi
    Lu, Humu
    Liu, Yonghong
    Wang, Xueni
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (02) : 1089 - 1104
12345